New research reveals that patients who come off popular GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who end traditional lifestyle programs.
Research printed in a leading medical journal demonstrates that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month after stopping.
"Users buying such treatments must be aware of the risk of quick rebound weight gain when the medication ends," cautioned researcher Dr. Susan Jebb.
That rate of recovery implies a return to starting weight in about one and a half years.
Comparing Treatments
The analysis, which examined 37 of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with conventional dieting.
Scientists point out that people who lose weight through dieting generally experience a less rapid creep back—around 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Doctors suggest the way of the injections is key to understanding the heightened rebound.
These medications mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement leads to appetite is no longer kept in check, making binge eating far more likely."
An Ongoing Disease?
The NHS advise the injections for people with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians argue that, due to the high risk of weight regain, the therapy should be considered ongoing.
This view is supported by drug manufacturers, who say that the results "emphasize the chronic character of obesity," similar to managing diseases like hypertension.
Patient Accounts
Users who have come off the jabs explain a intense return of appetite.
"It was like something flipping and you're instantly extremely hungry," recalled an individual.
This challenge is compounded if users have not adopted lasting dietary or behavioural changes during treatment.
Widespread Use
Survey data suggest that a significant number of people in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Adoption is more common among women compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while these medications are effective tools for weight loss, they are not a standalone solution and long-term success likely depends on integrated behavioural management.
